share_log

BioVie | 8-K: Current report

BioVie | 8-K: Current report

BioVie | 8-K：重大事件
美股SEC公告 ·  2024/09/24 06:21

Moomoo AI 已提取核心訊息

On September 23, 2024, BioVie Inc., a clinical-stage biopharmaceutical company, announced the entry into a placement agent agreement with ThinkEquity LLC for a public offering of shares and warrants. The offering includes up to 1,960,800 shares of BioVie's class A common stock at $1.53 per share and/or pre-funded warrants to purchase common stock at $1.5299 per warrant, along with common stock purchase warrants to buy additional shares. The gross proceeds are expected to be approximately $3 million before fees and expenses. The offering, made under BioVie's effective registration statement on Form S-3, is expected to close on September 25, 2024. The company plans to use the net proceeds for working capital and general corporate purposes. BioVie also issued a warrant to the placement agent, exercisable for 98,040 shares at $1.9125 per share. The announcement was accompanied by press releases detailing the offering and its pricing. BioVie specializes in developing treatments for advanced liver disease and neurological disorders, with drug candidates NE3107 for neurodegenerative diseases and BIV201 for liver cirrhosis.
On September 23, 2024, BioVie Inc., a clinical-stage biopharmaceutical company, announced the entry into a placement agent agreement with ThinkEquity LLC for a public offering of shares and warrants. The offering includes up to 1,960,800 shares of BioVie's class A common stock at $1.53 per share and/or pre-funded warrants to purchase common stock at $1.5299 per warrant, along with common stock purchase warrants to buy additional shares. The gross proceeds are expected to be approximately $3 million before fees and expenses. The offering, made under BioVie's effective registration statement on Form S-3, is expected to close on September 25, 2024. The company plans to use the net proceeds for working capital and general corporate purposes. BioVie also issued a warrant to the placement agent, exercisable for 98,040 shares at $1.9125 per share. The announcement was accompanied by press releases detailing the offering and its pricing. BioVie specializes in developing treatments for advanced liver disease and neurological disorders, with drug candidates NE3107 for neurodegenerative diseases and BIV201 for liver cirrhosis.
2024年9月23日，臨床階段生物製藥公司biovie宣佈與ThinkEquity LLC簽署了一份放置代理協議，用於公開發行股票和認股權證。該發行計劃包括最多1960800股biovie每股1.53美元的A類普通股，和/或可在1.5299美元每權證行權的預先擬購權證，以及可購買額外股份的普通股購買權證。募集的總收益預計將約爲300萬美元，不包括費用和開支。該發行是根據biovie在S-3表格上生效的註冊聲明進行的，預計將於2024年9月25日關閉。公司計劃將淨收益用於營運資金和一般公司用途。biovie還向放置代理發行了一份認股權證，行權價格爲每股1.9125美元，行權股數爲98040股。該公告還附有詳細介紹發行及定價情況的新聞稿。biovie專門從事發展高級肝病和神經紊亂的治療，藥物候選包括NE3107用於神經退行性疾病和BIV201用於肝硬化。
2024年9月23日，臨床階段生物製藥公司biovie宣佈與ThinkEquity LLC簽署了一份放置代理協議，用於公開發行股票和認股權證。該發行計劃包括最多1960800股biovie每股1.53美元的A類普通股，和/或可在1.5299美元每權證行權的預先擬購權證，以及可購買額外股份的普通股購買權證。募集的總收益預計將約爲300萬美元，不包括費用和開支。該發行是根據biovie在S-3表格上生效的註冊聲明進行的，預計將於2024年9月25日關閉。公司計劃將淨收益用於營運資金和一般公司用途。biovie還向放置代理發行了一份認股權證，行權價格爲每股1.9125美元，行權股數爲98040股。該公告還附有詳細介紹發行及定價情況的新聞稿。biovie專門從事發展高級肝病和神經紊亂的治療，藥物候選包括NE3107用於神經退行性疾病和BIV201用於肝硬化。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

獨立文件8  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間